Laiba Immad
1 min read
In This Article:
Pfizer Inc. (NYSE:PFE) has unveiled major advances in cancer research at the 2025 ASCO Annual Meeting, spotlighting robust five-year survival results for XTANDI (enzalutamide) combined with androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer. Data from the Phase 3 ARCHES trial show XTANDI plus ADT cuts the risk of death by 30%, with a 66% five-year survival rate versus 53% for ADT alone. XTANDI is now the first androgen receptor inhibitor to demonstrate such a long-term survival benefit, reinforcing its position as a standard of care for this patient group.
Pixabay/Public Domain
Despite these clinical milestones and ongoing innovation, including first-in-human studies of new oncology drugs, Pfizer Inc. (NYSE:PFE)’s shares rose just 2%, in line with broader market resilience amid renewed trade tensions. Over the past year, PFE’s total return, factoring in dividends, is down 14.32%, lagging the overall US pharmaceuticals sector.
Analysts see upside potential, with a consensus price target of $29.50, but note that future performance hinges on continued drug approvals, successful market expansion, and operational efficiency. Pfizer Inc. (NYSE:PFE)’s strategic collaborations and licensing agreements remain key as the company navigates competitive pressures and shifting revenue streams.
While we acknowledge the potential of PFE to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than PFE and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 10 Best Cancer Stocks to Invest in for Long-Term Gains and 10 Most Oversold Stocks to Buy According to Billionaires.
Disclosure: None.
